1st Quarter - Report

THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH for THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH

Firm
Client
Income
—
Expenses
$50,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS).

LobbyistCovered position, as disclosed
MEGAN MAY —
TED THOMPSON —
DUSTIN WATSON —
MASON ZEAGLER —

Contacted: Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); SENATE

Bills named: S. 1064 (118th), H.R. 2365 (118th), S. 652 (118th)

Medicare/Medicaid MMM

Increasing prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining prior authorization processes.

LobbyistCovered position, as disclosed
MASON ZEAGLER —

Contacted: Centers For Medicare and Medicaid Services (CMS)

Agriculture AGR

General education on risks of Parkinson's disease, including TCE, paraquat, air pollution, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S. 269, the Protect Americas Children from Toxic Pesticides Act (PACTPA). General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals.

LobbyistCovered position, as disclosed
MEGAN MAY —
TED THOMPSON —

Contacted: Environmental Protection Agency (EPA); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); SENATE

Bills named: S. 269 (118th)

Budget/Appropriations BUD

FY 2024 Appropriations bills including funding requests for Parkinson's research at: The Department of Defense within the FY 2024 Defense Appropriation bill (no bill introduced); The National Institute of Health and Centers for Disease Control and Prevention within the FY 2024 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill (no bill introduced); The Food and Drug Administration within the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill (no bill introduced); The Department of Veterans Affairs within the FY 2024 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill (no bill introduced).

LobbyistCovered position, as disclosed
MEGAN MAY —
DUSTIN WATSON —

Contacted: SENATE; Veterans Affairs, Dept of (VA); Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES

Pharmacy PHA

S.652 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Increasing prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining prior authorization processes

LobbyistCovered position, as disclosed
MASON ZEAGLER —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: S. 652 (118th)

Veterans VET

FY24 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.

LobbyistCovered position, as disclosed
TED THOMPSON —
DUSTIN WATSON —

Contacted: HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); SENATE

Environment/Superfund ENV

General education regarding environmental triggers of neurological disease and Parkinson's along with support for more research. S.269, the Protect America's Children from Toxic Pesticides Act (PACTPA). More protective standards for particulate matter pollution.

LobbyistCovered position, as disclosed
MEGAN MAY —
TED THOMPSON —

Contacted: Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA); SENATE

Bills named: S. 269 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.